2-氯-4-苯氧基喹唑啉 | 858027-20-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-4-苯氧基喹唑啉
• 英文名称: 2-chloro-4-phenoxyquinazoline
• 英文别名: 2-Chlor-4-phenoxy-chinazolin
• CAS: 858027-20-0
• 化学式: C₁₄H₉ClN₂O
• 分子量: 256.691
• InChiKey: ZAXXHUNCROLIFL-UHFFFAOYSA-N

物化性质

• 熔点：
  121 °C
• 沸点：
  367.8±24.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯-4-苯氧基喹唑啉 在 sodium azide 作用下， 以 二甲基亚砜 为溶剂， 反应 32.0h， 生成 5-phenoxytetrazolo[1,5-a]quinazoline
  参考文献：
  名称：

  5-烷氧基-四唑并[1,5-a]喹唑啉类抗惊厥和抗抑郁活性的合成与评价

  摘要：

  通过 2,4-二氯喹唑啉与各种酚或脂肪醇，然后与叠氮化钠反应，合成了几种 5-烷氧基-四唑并[1,5-a]喹唑啉衍生物。这些化合物的结构已通过IR、MS、1H-NMR和元素分析确证。使用最大电休克 (MES) 测试评估抗惊厥活性。大多数合成的化合物在 300 mg/kg 的剂量下显示出微弱的抗惊厥活性。通过强迫游泳试验研究抗抑郁活性。两种化合物，即5-(己氧基)四唑并[1,5-a]喹唑啉和5-(4-甲氧基苯氧基)四唑并[1,5-a]喹唑啉，显示出显着的抗抑郁活性，将不动时间减少了62.2和51.7 % 在 100 mg/kg 剂量水平。

  DOI：

  10.1002/ardp.200900119
• 作为产物：
  描述：

  2,4-二氯喹唑啉 、 sodium phenoxide 在 苯酚 作用下， 生成 2-氯-4-苯氧基喹唑啉
  参考文献：
  名称：

  QUINAZOLINES. I. THE INTERACTION OF 2,4-DICHLOROQUINAZOLINE WITH SODIUM ALCOHOLATES AND SODIUM PHENATES WITH THE REPLACEMENT OF ONE HALOGEN TO FORM HALOGEN-OXYGEN ETHERS

  摘要：

  DOI：

  10.1021/ja01372a041

文献信息

• Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
  申请人：Smits Rogier Adriaan

  公开号：US20100016293A1

  公开（公告）日：2010-01-21

  Compounds that interact with the histamine H4 receptor, and which may be useful for treating or preventing disorders and conditions mediated by the histamine H4 receptor, e.g. inflammation, are of formula (I) wherein Q is CR 1 or N; X is CR 2 or N, provided that Q and X are not both N; Y is CR 3 or N; Z is CH or N; R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; and R7 is a heterocyclic radical including one or more N atoms; or a pharmaceutically acceptable salt, ester or solvate thereof.

  与组织胺H4受体相互作用的化合物，可能用于治疗或预防由组织胺H4受体介导的疾病和症状，如炎症，其化学式为(I)，其中Q为CR1或N；X为CR2或N，前提是Q和X不同时为N；Y为CR3或N；Z为CH或N；R1、R2、R3、R4、R5和R6独立地为H、F、Cl、Br、I或可选择含有一个或多个杂原子的碳氢基团；R7为包含一个或多个N原子的杂环基团；或其药用盐、酯或溶剂化合物。
• COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE
  申请人：Chen Li

  公开号：US20130196974A1

  公开（公告）日：2013-08-01

  A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R 1 to R 10 , A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

  一种化合物的公式（I），以及其药学上可接受的盐，其中R1至R10，A，Q，X和Y的定义如规范和索赔中所述，以及其作为药物用于治疗或预防呼吸道合胞病毒疾病的用途。
• Discovery of Quinazolines as Histamine H₄ Receptor Inverse Agonists Using a Scaffold Hopping Approach
  作者：Rogier A. Smits、Iwan J. P. de Esch、Obbe P. Zuiderveld、Joachim Broeker、Kamonchanok Sansuk、Elena Guaita、Gabriella Coruzzi、Maristella Adami、Eric Haaksma、Rob Leurs

  DOI：10.1021/jm800876b

  日期：2008.12.25

  From a series of small fragments that was designed to probe the histamine H-4 receptor (H4R), we previously described quinoxaline-containing fragments that were grown into high affinity H4R ligands in a process that was guided by pharmacophore modeling. With a scaffold hopping exercise and using the same in silico models, we now report the identification and optimization of a series of quinazoline-containing H4R compounds. This approach led to the discovery of 6-chloi-o-N-(furan-3-yl)methyl)2-(4-methylpiperzin-1-yl)quinazolin-4-amine (VUF10499, 54) and 6-chloro-2-(4-methylpiperazin-1-yl)-N-(thiophen-2-ylmethyl)quinazolin-4-amine (VUF10497, 55) as potent human H4R inverse agonists (pK(i) = 8.12 and 7.57, respectively). Interestingly, both compounds also possess considerable affinity for the human histamine Hi receptor (H1R) and therefore represent a novel class of dual action H1R/H4R ligands, a profile that potentially leads to added therapeutic benefit. Compounds from this novel series of quirlazolines are antagonists at the rat H4R and were found to possess anti-inflammatory properties in vivo in the rat.
• Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy
  作者：Zhao-Sen Zeng、Qiu-Qin He、Yong-Hong Liang、Xiao-Qing Feng、Fen-Er Chen、Erik De Clercq、Jan Balzarini、Christophe Pannecouque

  DOI：10.1016/j.bmc.2010.05.081

  日期：2010.7

  Molecular hybridization of the known anti-HIV-1 template DPC083 and etravirine based on docking model overlay has been generated a novel series of diarylbenzopyrimidine analogues (DABPs) (5a-z). These new hybrids were assessed for their activity against HIV in MT-4 cell cultures. Most of these compounds showed good activity against wild-type HIV-1 and mutant viruses. In particular, compound 5r showed the most potent activity against wild-type HIV-1 with an EC50 value of 1.8 nM, and with a selectivity index up to 111,954. It also proved more active against mutant L100I, K103N, Y188L, and K103N + Y181C RT HIV-1 strains than efavirenz. (C) 2010 Elsevier Ltd. All rights reserved.
• QUINAZOLINES. IV. ALCOHOLYSIS IN THE QUINAZOLINE SERIES AND THE PREPARATION OF SOME MIXED DIETHERS OF QUINAZOLINE
  作者：N. A. Lange、F. E. Sheibley

  DOI：10.1021/ja01350a024

  日期：1932.11